{"id":"low-dose-atorvastatin","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Muscle pain or myalgia"},{"rate":"1-3","effect":"Elevated liver enzymes"},{"rate":"1-2","effect":"Headache"},{"rate":"0.1","effect":"Rhabdomyolysis"}]},"_chembl":{"chemblId":"CHEMBL1487","moleculeType":"Small molecule","molecularWeight":"558.65"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atorvastatin is a statin that competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. By reducing hepatic cholesterol production, it lowers circulating LDL cholesterol and triglycerides while modestly increasing HDL cholesterol. Low-dose formulations maintain efficacy while potentially reducing adverse effects associated with higher doses.","oneSentence":"Low-dose atorvastatin inhibits HMG-CoA reductase to reduce cholesterol synthesis and lower LDL cholesterol levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:53:09.692Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia"},{"name":"Cardiovascular disease prevention"},{"name":"Dyslipidemia"}]},"trialDetails":[{"nctId":"NCT05488067","phase":"PHASE4","title":"Atorvastatin Therapy on Xanthoma in Alagille Syndrome","status":"COMPLETED","sponsor":"Children's Hospital of Fudan University","startDate":"2022-03-22","conditions":"Alagille Syndrome, Atorvastatin, Xanthoma","enrollment":15},{"nctId":"NCT07359105","phase":"NA","title":"Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study)","status":"RECRUITING","sponsor":"Sin Gon Kim","startDate":"2026-03-09","conditions":"Dyslipidemia Associated With Type II Diabetes Mellitus","enrollment":2186},{"nctId":"NCT06782243","phase":"NA","title":"Comparison of High and Moderate Intensity Statins in Achieving the Target LDL-C Level After Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2024-12-20","conditions":"Acute Coronary Syndrome","enrollment":190},{"nctId":"NCT05462262","phase":"NA","title":"Intensive Lipid-lowering for Plaque and Major Adverse Cardiovascular Events in Low to Intermediate 10-year ASCVD Risk Population","status":"ENROLLING_BY_INVITATION","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2022-10-10","conditions":"Coronary Artery Disease Progression","enrollment":2900},{"nctId":"NCT06615284","phase":"PHASE1","title":"A Study of Atorvo+™ in Healthy Adult Participants","status":"COMPLETED","sponsor":"Indication Bioscience LLC","startDate":"2025-01-28","conditions":"Coronary Heart Disease, Dyslipidemias","enrollment":24},{"nctId":"NCT07278830","phase":"PHASE2","title":"A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia","status":"COMPLETED","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2023-06-02","conditions":"Hypercholesterolemia and Mixed Dyslipidemia","enrollment":214},{"nctId":"NCT06796660","phase":"EARLY_PHASE1","title":"Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients","status":"NOT_YET_RECRUITING","sponsor":"Liu Zhanghong","startDate":"2025-09-01","conditions":"Renal Insufficiency, Chronic","enrollment":70},{"nctId":"NCT03360916","phase":"PHASE4","title":"Impact of Statin Therapy on Adaptations to Aerobic Exercise","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2018-02-01","conditions":"Cardiovascular Diseases","enrollment":52},{"nctId":"NCT03127631","phase":"NA","title":"A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients","status":"RECRUITING","sponsor":"McMaster University","startDate":"2015-10-21","conditions":"Prostate Cancer, Cardiovascular Disease","enrollment":6000},{"nctId":"NCT03351998","phase":"PHASE4","title":"Impact of Statin Therapy on Muscle Mitochondrial Function and Aerobic Capacity","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2018-02-22","conditions":"Mitochondrial Diseases","enrollment":68},{"nctId":"NCT04656028","phase":"NA","title":"Genetic Testing and Motivational Counseling for FH","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Center for Therapy and Preventive Medicine","startDate":"2020-06-15","conditions":"Hypercholesterolemia, Familial, Hypercholesterolemia, Familial, 1, Hypercholesterolemia, Familial, 2","enrollment":180},{"nctId":"NCT02726555","phase":"PHASE3","title":"The Efficacy and Safety of Combined Therapy With Red Yeast Rice and Low-dose Statin：Comparing With Standardized Statin","status":"RECRUITING","sponsor":"Wenzhou Medical University","startDate":"2015-11","conditions":"Dyslipidemia, Atherosclerosis","enrollment":240},{"nctId":"NCT05250596","phase":"PHASE2","title":"COLchicine On-admission to Reduce Inflammation in Acute Coronary Syndrome (COLOR-ACS)","status":"COMPLETED","sponsor":"Azienda USL Toscana Centro","startDate":"2022-02-24","conditions":"Non ST Segment Elevation Acute Coronary Syndrome","enrollment":182},{"nctId":"NCT06239714","phase":"PHASE1","title":"A Study to Evaluate SGB-3403 in Healthy Volunteers and Subjects With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)","status":"UNKNOWN","sponsor":"Suzhou Sanegene Bio Inc.","startDate":"2024-02-18","conditions":"Hyperlipidemias","enrollment":64},{"nctId":"NCT06083337","phase":"NA","title":"Vascular Inflammation ReDuction and Perivascular Fat Imaging by Computed Tomography","status":"UNKNOWN","sponsor":"Hippocration General Hospital","startDate":"2022-01-22","conditions":"Coronary Artery Disease, Atheroscleroses, Coronary, Vascular Inflammation","enrollment":140},{"nctId":"NCT01980823","phase":"EARLY_PHASE1","title":"Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer","status":"COMPLETED","sponsor":"Columbia University","startDate":"2013-10","conditions":"Breast Cancer, Breast Tumors, Cancer of Breast","enrollment":23},{"nctId":"NCT04666389","phase":"NA","title":"The Role of Statins in the Prevention of Contrast-induced Acute Kidney Injury in Patients With Cardiovascular Diseases","status":"COMPLETED","sponsor":"I.M. Sechenov First Moscow State Medical University","startDate":"2020-10-15","conditions":"Contrast-induced Acute Kidney Injury, Cardiovascular Diseases","enrollment":150},{"nctId":"NCT05589454","phase":"PHASE4","title":"Intracranial Hemorrhage Risk of Intensive Statin in Acute Ischemic Stroke With Cerebral Microbleeds","status":"NOT_YET_RECRUITING","sponsor":"Sichuan Provincial People's Hospital","startDate":"2023-01","conditions":"Acute Ischemic Stroke, Cerebral Microbleeds","enrollment":344},{"nctId":"NCT05298475","phase":"PHASE4","title":"Low-dose PCSK9 Inhibitor Combined With Stains on Serum Lipids in Chinese Population With Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-04-01","conditions":"Acute Coronary Syndrome","enrollment":100},{"nctId":"NCT03882996","phase":"PHASE3","title":"A Long-term Safety and Tolerability Study of Ezetimibe Plus Atorvastatin in Participants With Coronary Heart Disease, Multiple Risk Factors, or Hypercholesterolemia Not Controlled by Atorvastatin (P01418/MK-0653-032)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-10-06","conditions":"Hypercholesterolemia","enrollment":432},{"nctId":"NCT03355027","phase":"NA","title":"Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2017-11-30","conditions":"Atherosclerosis, Cardiovascular Diseases","enrollment":60},{"nctId":"NCT03877783","phase":"NA","title":"DEMAND - Multifactorial Study to Reduce Dementia in People With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Umeå University","startDate":"2020-10-19","conditions":"Type 2 Diabetes Mellitus, Mild Cognitive Impairment","enrollment":10},{"nctId":"NCT00442325","phase":"PHASE4","title":"Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-01","conditions":"Coronary Arteriosclerosis, Diabetes Mellitus, Type 2, Cerebrovascular Accident","enrollment":595},{"nctId":"NCT00645151","phase":"PHASE4","title":"A Study Of The Efficacy Of Atorvastatin In Lowering Cholesterol In Latin American Patients With High Cholesterol","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-04","conditions":"Dyslipidemias","enrollment":512},{"nctId":"NCT00442845","phase":"PHASE4","title":"Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-01","conditions":"Coronary Arteriosclerosis, Diabetes Mellitus, Type 2, Cerebrovascular Accident","enrollment":2080},{"nctId":"NCT00647543","phase":"PHASE4","title":"Atorvastatin Study For The Treatment Of High Cholesterol In Patients From Thailand","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-08","conditions":"Dyslipidemias","enrollment":242},{"nctId":"NCT03510715","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-08-31","conditions":"Hypercholesterolemia","enrollment":18},{"nctId":"NCT01890967","phase":"PHASE2","title":"A Study of LY3015014 in Participants With High Cholesterol","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-06","conditions":"Hypercholesterolemia","enrollment":527},{"nctId":"NCT02938949","phase":"PHASE4","title":"Alirocumab in Patients With Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2017-01","conditions":"Myocardial Infarction, Hypercholesterolemia","enrollment":20},{"nctId":"NCT01663402","phase":"PHASE3","title":"ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-10","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":18924},{"nctId":"NCT02584504","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-11-30","conditions":"Hypercholesterolemia","enrollment":163},{"nctId":"NCT00559962","phase":"PHASE2","title":"Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2007-10","conditions":"Hyperlipidemia","enrollment":260},{"nctId":"NCT02125682","phase":"PHASE4","title":"The HDL Particle Protection Study","status":"COMPLETED","sponsor":"Hotel Dieu de France Hospital","startDate":"2012-01","conditions":"Dyslipidemia in Patients With Diabetes Mellitus","enrollment":16},{"nctId":"NCT03047772","phase":"PHASE2","title":"Transplantation Efficacy of Autologous Bone Marrow Mesenchymal Stem Cells With Intensive Atorvastatin in AMI Patients","status":"UNKNOWN","sponsor":"Yuejin Yang","startDate":"2018-03-06","conditions":"Myocardial Infarction, Stem Cell Transplantation, Angioplasty, Transluminal, Percutaneous Coronary","enrollment":124},{"nctId":"NCT03031119","phase":"PHASE1","title":"Multiple Ascending Dose and DDI Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-01","conditions":"Healthy Volunteers","enrollment":62},{"nctId":"NCT02518516","phase":"","title":"High Potency Statins and Acute Kidney Injury","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2011-01","conditions":"Hypercholesterolemia","enrollment":2067639},{"nctId":"NCT02518503","phase":"","title":"High Potency Statins and the Risk of Diabetes","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2012-07","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Disease","enrollment":136966},{"nctId":"NCT01623115","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-07","conditions":"Hypercholesterolemia","enrollment":486},{"nctId":"NCT00570752","phase":"PHASE2","title":"Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-12","conditions":"Vascular Diseases","enrollment":72},{"nctId":"NCT00768638","phase":"PHASE4","title":"Study of Atorvastatin Dose Dependent Reduction of Proteinuria","status":"COMPLETED","sponsor":"Laval University","startDate":"2008-10","conditions":"Chronic Kidney Disease","enrollment":23},{"nctId":"NCT00368589","phase":"","title":"Effects Of Atorvastatin On Macrophage Activity And Plaque Inflammation Using Magnetic Resonance Imaging","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-07","conditions":"Atherosclerotic Carotid Disease, Atheroma, Atherosclerosis","enrollment":47},{"nctId":"NCT00700037","phase":"PHASE4","title":"Change in Plaque Characteristics With Atorvastatin","status":"COMPLETED","sponsor":"Wakayama Medical University","startDate":"2009-08","conditions":"Acute Coronary Syndrome, Atherosclerosis, Dyslipidemia","enrollment":70},{"nctId":"NCT01544751","phase":"NA","title":"Nonalcoholic Fatty Liver Disease (NAFLD) Pharmacological Treatment: Metformin Versus Atorvastatin","status":"UNKNOWN","sponsor":"Prof Antonino Belfiore","startDate":"2011-09","conditions":"Nonalcoholic Fatty Liver Disease (NAFLD)","enrollment":150},{"nctId":"NCT02001883","phase":"PHASE4","title":"Low-dose Statins and Nutraceuticals in High-intensity Statin-intolerant Patients","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2013-11","conditions":"Coronary Artery Disease","enrollment":100},{"nctId":"NCT00065806","phase":"PHASE3","title":"Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)","status":"COMPLETED","sponsor":"Laura Schanberg","startDate":"2003-09","conditions":"Lupus Erythematosus, Systemic","enrollment":221},{"nctId":"NCT01200056","phase":"PHASE4","title":"Virtual Histology Findings and Effects of Varying Doses of Atorvastatin Treatment","status":"COMPLETED","sponsor":"Prof. Stephen Lee","startDate":"2007-08","conditions":"Coronary Disease, Ultrasonography, Interventional, Hydroxymethylglutaryl-CoA Reductase Inhibitors","enrollment":40},{"nctId":"NCT01222182","phase":"","title":"Statin Interchange by Pharmacist Collaborative Practice Agreement (CPA)","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2009-09","conditions":"Hypercholesterolemia","enrollment":260},{"nctId":"NCT01013103","phase":"PHASE4","title":"Pleiotropic Effects of Atorvastatin in High Cardiovascular Risk Patients","status":"COMPLETED","sponsor":"Hippocration General Hospital","startDate":"2007-10","conditions":"Coronary Artery Disease, HMG-CoA Reductase Inhibitor Toxicity, Atherosclerosis","enrollment":72},{"nctId":"NCT00615823","phase":"PHASE2","title":"Atorvastatin in Pulmonary Hypertension","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2007-02","conditions":"Hypertension, Pulmonary","enrollment":220},{"nctId":"NCT00736463","phase":"PHASE4","title":"Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc)","status":"UNKNOWN","sponsor":"Oregon Health and Science University","startDate":"2005-01","conditions":"HDL Cholesterol","enrollment":80},{"nctId":"NCT01306565","phase":"NA","title":"High Dose and Low Dose of Atorvastatin in Patients With Unstable Angina and NSTEMI (Non ST Elevation MI)","status":"COMPLETED","sponsor":"Hormozgan University of Medical Sciences","startDate":"2009-01","conditions":"Cardiovascular Disease","enrollment":100},{"nctId":"NCT01187992","phase":"PHASE3","title":"Full-dose Atorvastatin After Acute Coronary Syndrome (ACS) in Non-revascularisable Coronary Artery Disease","status":"TERMINATED","sponsor":"San Filippo Neri General Hospital","startDate":"2003-09","conditions":"Acute Coronary Syndrome, Coronary Artery Disease","enrollment":290},{"nctId":"NCT01063426","phase":"PHASE4","title":"Re-STOP DVT: Reload of High Dose Atorvastatin for Preventing Deep Vein Thrombosis in Statin Users","status":"UNKNOWN","sponsor":"Hallym University Medical Center","startDate":"2009-11","conditions":"Thrombosis, Prevention, Surgery","enrollment":180},{"nctId":"NCT00654537","phase":"PHASE3","title":"STELLAR-Rosuvastatin vs. Atorvastatin, Pravastatin, Simvastatin Across Dose Ranges","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2001-04","conditions":"Hypercholesterolemia","enrollment":5625},{"nctId":"NCT00329173","phase":"PHASE3","title":"PULSAR - A Prospective Study to Evaluate the Utility of Low Doses of the Statins Atorvastatin and Rosuvastatin.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-11","conditions":"Hypercholesterolaemia","enrollment":1000},{"nctId":"NCT00689442","phase":"PHASE2","title":"Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels","status":"COMPLETED","sponsor":"Akros Pharma Inc.","startDate":"2004-01","conditions":"Dyslipidemia","enrollment":105}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":145,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lipitor5"],"phase":"marketed","status":"active","brandName":"low-dose atorvastatin","genericName":"low-dose atorvastatin","companyName":"Wakayama Medical University","companyId":"wakayama-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low-dose atorvastatin has been studied in clinical trials for conditions such as hyperlipidemias, contrast-induced acute kidney injury, cardiovascular diseases, coronary artery disease, and HMG-CoA Reductase Inhibitor toxicity. Atorvastatin, a medication that inhibits HMG-CoA reductase, has been evaluated in a phase 1 study (NCT06239714) for its effects on elevated low-density lipoprotein cholesterol (LDL-C).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}